Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma

BACKGROUND: Activated B cell-like subtype of diffuse large B cell lymphoma (ABC-DLBCL) presents aggressive clinical courses and poor prognosis. Targeting key pathways may raise the possibility of improving clinical outcomes. METHODS: The synergetic effects were assessed by CCK-8 assay and measured b...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Exp Clin Cancer Res
Egile Nagusiak: Jin, Zhen, Qing, Kai, Ouyang, Yuan, Liu, Zhao, Wang, Wenfang, Li, Xiaoyang, Xu, Zizhen, Li, Junmin
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2016
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4806505/
https://ncbi.nlm.nih.gov/pubmed/27009084
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-016-0327-x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak